Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
=== Biological computers === A biological computer refers to an engineered biological system that can perform computer-like operations, which is a dominant paradigm in synthetic biology. Researchers built and characterized a variety of logic gates in a number of organisms, and demonstrated both analog and digital computation in living cells. They demonstrated that bacteria can be engineered to perform both analog and/or digital computation. In 2007, in human cells, research demonstrated a universal logic evaluator that operates in mammalian cells. Subsequently, researchers utilized this paradigm to demonstrate a proof-of-concept therapy that uses biological digital computation to detect and kill human cancer cells in 2011. In 2016, another group of researchers demonstrated that principles of computer engineering can be used to automate digital circuit design in bacterial cells. In 2017, researchers demonstrated the 'Boolean logic and arithmetic through DNA excision' (BLADE) system to engineer digital computation in human cells. In 2019, researchers implemented a perceptron in biological systems opening the way for machine learning in these systems.
Article 38(1) of Ba'athist Syria's constitution stated that "no citizen may be deported from the country, or prevented from returning to it". This, along with Article 13 of the Universal Declaration of Human Rights creates a general legal right to travel internationally. As well as preventing citizens from leaving Syria, there have also been many instances of citizens being prevented from returning to Syria, whether they left illegally or not. A positive step in regards to this was taken on 28 April 2015, when it was announced by Syrian authorities that citizens who had previously fled the war would be able to re-attain passports without a review by the intelligence service, or going through the Department of emigration and passports. These citizens had fled the country illegally and either not taken their passports, or lost them. Human Rights Watch reported in October 2021 that refugees who went back to Syria by their own choice, "suffered severe human rights abuses and persecution at the hands of Syrian government and affiliated militias, including torture, extra-judicial killings, and kidnappings."
==== Instrument and application integration ==== Modern LIMS offer an increasing amount of integration with laboratory instruments and applications. A LIMS may create control files that are "fed" into the instrument and direct its operation on some physical item such as a sample tube or sample plate. The LIMS may then import instrument results files to extract data for quality control assessment of the operation on the sample. Access to the instrument data can sometimes be regulated based on chain of custody assignments or other security features if need be. Modern LIMS products now also allow for the import and management of raw assay data results. Modern targeted assays such as qPCR and deep sequencing can produce tens of thousands of data points per sample. Furthermore, in the case of drug and diagnostic development as many as 12 or more assays may be run for each sample. In order to track this data, a LIMS solution needs to be adaptable to many different assay formats at both the data layer and import creation layer, while maintaining a high level of overall performance. Some LIMS products address this by simply attaching assay data as BLOBs to samples, but this limits the utility of that data in data mining and downstream analysis.
Scutellaria is a genus of flowering plants in the mint family, Lamiaceae. They are known commonly as skullcaps. The generic name is derived from the Latin scutella, meaning "a small dish, tray or platter", or "little dish", referring to the shape of the calyx. The common name alludes to the resemblance of the same structure to "miniature medieval helmets". The genus has a subcosmopolitan distribution, with species occurring nearly worldwide, mainly in temperate regions.
Sources: en.wikipedia.org
=== Agronomy study === After the initial sowing into seed beds, seedlings at 3 days old can be transplanted into pots. Seedlings typically reach 20-25 centimetres tall after 20 weeks in the nursery, at which point they can be planted out into the field; direct sowing is possible, but its viability largely depends on soil moisture and the degree of insect/rodent threats. Preliminary ploughing "contributes to proper establishment of seedlings in the field with a success rate of 82% four years" in some cases after planting. Seeds can be treated with concentrated sulphuric acid "in a concentration of 97% for 10 minutes and then immersed in water for 24 hours to break their dormancy period." Seedlings grow comparatively fast – they can reach a height of 1 metre in just 1 year. They will begin to flower at 5–7 years during the dry season in the Sahel (December to April), while occurring slightly earlier in less dry regions. The tree is pollinated primarily by bats, but can also occur by way of "honeybees, flies, wasps, ants, tenebrionid beetles and tettigometid bugs." Fruiting can occur at anywhere from 5–10 years, and they will start to ripen just before the first rains and continue over most of the season. Foliage of locust bean has been found to contribute to soil fertility improvement. In one experiment, the isolated relative effect of locust bean in the third year of the experiment was 86%, compared to 138% for neem, a related tree.
The previous life: the first two nidanas, namely ignorance and mental fabrications. They are basis for the events in the present. Nyanatiloka, writing from a traditional Theravada perspective, calls these "karma process" (kamma-bhava). The present life: The third to the tenth nidanas (consciousness, nama-rupa, the sense bases, contact, feeling, craving, clinging, becoming) relate to the present life. This begins with the descent of vijnana (consciousness, perception) into the womb. Nyanatiloka notes that nidanas 3-7 are part of the "rebirth process" (uppatti-bhava) and nidanas are 8-10 are "karma process". The future life: The last two nidanas (birth, old age and death) represent the future lives conditioned by the present causes. Nyanatiloka states these last two nidanas are a "rebirth process". Bhikkhu Bodhi notes that this distribution of the 12 nidanas into three lives "is an expository device employed for the purpose of exhibiting the inner dynamics of the round. It should not be read as implying hard and fast divisions, for in lived experience the factors are always intertwined." Furthermore, Bodhi argues that these twelve causes are not something hidden, but are "the fundamental pattern of experience" which "always present, always potentially accessible to our awareness." Nagarjuna's Pratityasamutpada-hrdaya-karika also outlines the 12 nidanas as a rebirth process.
=== Other uses === Clonidine also has several off-label uses, and has been prescribed to treat psychiatric disorders including stress, hyperarousal caused by post-traumatic stress disorder, borderline personality disorder, and other anxiety disorders. It has also been studied as a way to calm acute manic episodes. Clonidine can be used in restless legs syndrome. It can also be used to treat facial flushing and redness associated with rosacea. It has also been successfully used topically in a clinical trial as a treatment for diabetic neuropathy. Clonidine can also be used for migraine headaches and hot flashes associated with menopause. Clonidine has also been used to treat refractory diarrhea associated with irritable bowel syndrome, fecal incontinence, diabetes, diarrhea associated with opioid withdrawal, intestinal failure, neuroendocrine tumors, and cholera. Clonidine can be used in the treatment of Tourette syndrome (specifically for tics). Clonidine has also had some success in clinical trials for helping to remove or ameliorate the symptoms of hallucinogen persisting perception disorder (HPPD). Photoswitchable derivatives of clonidine have been developed that behave as α receptor agonists (adrenoswitches). They can be applied topically in the cornea and allow controlling with light the pupillary reflex of blinded mice and locomotion in zebrafish larvae.
==== Host genetic factors ==== The organism that is the target of an infecting action of a specific infectious agent is called the host. The host harboring an agent that is in a mature or sexually active stage phase is called the definitive host. The intermediate host comes in contact during the larvae stage. A host can be anything living and can attain to asexual and sexual reproduction. The clearance of the pathogens, either treatment-induced or spontaneous, can be influenced by the genetic variants carried by individual patients. For instance, for genotype 1 hepatitis C treated with Pegylated interferon-alpha-2a or Pegylated interferon-alpha-2b (brand names Pegasys or PEG-Intron) combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in the treatment-induced clearance of the virus. This finding, originally reported in Nature, showed that genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve a sustained virological response after treatment than others. Later report from Nature demonstrated that the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.
==== Medical organizations ==== American Association for Anatomy, professional organization advancing anatomical sciences research and education Advanced Accelerator Applications, a radiopharmaceutical company
Sources: en.wikipedia.org
=== Drug delivery === Cyclodextrins are ingredients in more than 30 different approved medicines. With a hydrophobic interior and hydrophilic exterior, cyclodextrins form complexes with hydrophobic compounds. Alpha-, beta-, and gamma-cyclodextrin are all generally recognized as safe by the U.S. FDA. They have been applied for delivery of a variety of drugs, including hydrocortisone, prostaglandin, nitroglycerin, itraconazole, chloramphenicol. The cyclodextrin confers solubility and stability to these drugs. The inclusion compounds of cyclodextrins with hydrophobic molecules are able to penetrate body tissues, these can be used to release biologically active compounds under specific conditions. In most cases the mechanism of controlled degradation of such complexes is based on pH change of water solutions, leading to the loss of hydrogen or ionic bonds between the host and the guest molecules. Alternative means for the disruption of the complexes take advantage of heating or action of enzymes able to cleave α-1,4 linkages between glucose monomers. Cyclodextrins were also shown to enhance mucosal penetration of drugs.
=== Fibroblast growth factor === Platelet-derived growth factors (PDGFs) are polypeptides found in various tissues, including bone, where it was originally postulated that it could act as an autologous regulator of bone remodeling. This protein has been initially isolated in human platelets, and is composed of two different polypeptide chains A and B. The combination of these polypeptides form the homodimeric (AA) or (BB), or heterodimeric (AB) chains of PDGF. Fibroblast growth factor (FGF) signaling cascade is started by the binding of 2 growth factors to the FGFR. Dimerization takes place and initiates the transphosphorylation of each receptor. These phosphorylation sites act as docking sites for proteins so they may induce downstream signaling. These proteins consist of FRS2-alpha and PLC-gamma. FRS2-alpha acts as a scaffold protein to hold GAB1 and GRB2 which then proteins bind to SHP2 and SOS. These several proteins act together to activates the Ras pathway (induces cell proliferation and differentiation) and the PI3K pathway (induces survival and cell fate determination). On the other side of the dimerized receptors, PLC-gamma activates DAG and IP3 which yield PKC and calcium ions. PKC and calcium will ultimately induce morphology, migration, and adhesion.
drug cartels in moving money to the U.S. While regulators have flagged money laundering problems at HSBC for nearly a decade, the bank continued to avoid compliance. In December 2012, HSBC settled for a $1.93 billion fine.
=== Cost === GLP-1 agonists are more expensive than other treatments for type 2 diabetes. A study compared the cost-effectiveness of GLP-1 agonists to long-acting insulin in a Taiwanese population with type 2 diabetes. In people with cardiovascular disease (CVD), GLP-1 agonists were estimated to save money due to fewer cardiovascular incidents. In people without CVD, the cost per QALY was $9,093. In the United States, cost is the highest barrier to GLP-1 agonist usage and was reported as the reason for discontinuation in 48.6% of people who stopped using the drugs. According to a 2023 study, GLP-1 agonists were not cost-effective for pediatric obesity in the U.S. As of late 2025, prices had dropped substantially. In 2025 it was estimated that Medicare coverage of GLP-1RA agonists for obesity in the United States would increase federal spending by $69.5 billion over a decade. Mixed results have been found when economic evaluations of glucagon like peptide-1 (GLP-1) receptor agonists have been done, specifically in response to its use for obesity treatment in people without diabetes. A 2026 review concluded that, due to their high acquisition costs, GLP-1 receptor agonists are generally not cost-effective compared to lifestyle interventions or no treatment at all from a healthcare-payer perspective. The analysis also reported that cost-effectiveness outcomes vary drastically depending on assumptions related to treatment duration, long-term weight maintenance, and the time horizon of the specific model.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.